Sequence and structural features of RNA aptamer against myasthenic autoantibodies

Oligonucleotides

Volumn 19, Issue 3, 2009, Pages 273-279

  Cho, Jung Sun ^a   Lee, Seong Wook ^a  

^a Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; AUTOANTIBODY; CHOLINERGIC RECEPTOR; RNA APTAMER; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MYASTHENIA GRAVIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; AUTOANTIBODIES; BASE SEQUENCE; CELL LINE, TUMOR; HUMANS; IMMUNOLOGIC FACTORS; MYASTHENIA GRAVIS; NUCLEIC ACID CONFORMATION; RATS; RECEPTORS, CHOLINERGIC;

RATTUS;

EID: 70349284905     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0201     Document Type: Article

References (24)

1. DRACHMAN, D.B. (1994). Myasthenia gravis. N. Engl. J. Med. 330, 1797-1810.
2. ELLINGTON, A.D., and SZOSTAK, J.W. (1990). In vitro selection of RNA molecules that bind specif c ligands. Nature. 346, 818-822.
3. GRAUS, Y.F., DE BAETS, M.H., PARREN, P., BERRIH-AKNIN, S., WOKKE, J., VRIESMAN, P., and BURTON, D.R. (1997). Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients ref ect predominant specif cities in serum and block the action of pathogenic serum antibodies. J. Immunol. 158, 1919-1929. (Pubitemid 127469552)
4. HWANG, B., CHO, J.S., YEO, H.J., KIM, J.H., CHUNG, K.M., HAN, K., JANG, S.K., and LEE, S.W. (2004). Isolation of specif c and high-aff nity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA. 10, 1277-1290.
5. HWANG, B., and LEE, S.W. (2002). Improvement of RNA aptamer activity again st myasthen ic autoantibodies by extended sequence selection. Biochem. Biophys. Res. Comm. 290, 656-662.
6. LEE, S.W., and SULLENGER, B. (1996). Isolation of a nuclease resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J. Exp. Med. 194, 315-324.
7. LEE, S.W., and SULLENGER, B. (1997). Isolation of a nuclease-resis-tant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat. Biotechnol. 15, 41-45.
8. LINDSTROM, J., SHELTON, D., and FUGII, Y. (1988). Myasthenia gravis. Adv. Immunol. 42, 233-284.
9. LUTHER, M.A., SCHOEPFER, R., WHITING, P., CASEY, B., BLATT, Y., MONTAL, M.S., MONTAL, M., and LINDSTROM, J. (1989). A muscle acetylcholine receptor is expressed in the human cerebel-lar medulloblastoma cell line TE671. J. Neurosci. 9, 1082-1096.
10. NG, E.W.M., SHIMA, D.T., CALIAS, P., CUNNINGHAM, E.T. Jr., GUYER, D.R., and ADAMIS, A.P. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev. Drug Discov. 5, 123-132.
11. PROTOPAPADAKIS, E., KOKLA, A., TZARTOS, S.J., and MAMALAKI, A. (2005). Isolation and characterization of human antiacetylcholine receptor monoclonal antibodies from trans-genic mice expressing human immunoglobulin loci. Eur. J. Immunol. 35, 1960-1968.
12. QUE-GEWIRTH, N.S., and SULLENGER, B.A. (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther. 14, 283-291.
13. SATHASIVAM, S. (2008). Steroids and immunosuppressant drugs in myasthenia gravis. Nat. Clin. Pract. Neurol. 4, 317-327.
14. SIDERIS, S., LAGOUMINTZIS, G., KORDAS, G., KOSTELIDOU, K., SOTIRIADIS, A., POULAS, K., and TZARTOS, S.J. (2007). Isolation and functional characterization of anti-acetylcholine receptor subunit-specif c autoantibodies from myasthenic patients: receptor loss in cell culture. J. Neuroimmunol. 189, 111-117.
15. SOPHIANOS, D., and TZARTOS, S. (1989). Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenia gravis. J. Autoimmun. 2, 777-789.
16. STRATTON, M.R., DARLING, J., PIKINGTON, G.J., LANTOS, P.L., REEVES, B.R., and COOPER, C.S. (1989). Characterization of the human cell line TE671. Carcinogenesis. 10, 899-905.
17. TUERK, C., and GOLD, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 249, 505-510.
18. TZARTOS, S.J., RAND, D.E., EINARSON, B.L., and LINDSTROM, J.M. (1981). Mapping of surface structures of electrophorous ace-tylcholine receptor using monoclonal antibodies. J. Biol. Chem. 256, 8635-8645.
19. TZARTOS, S.J., SEYBOLD, M.E., and LINDSTROM, J.M. (1982). Specif cities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 79, 188-192.
20. VENKATESH, N., IM, S.H., BALASS, M., FUCHS, S., and KATCHALSKI-KATZIR, E. (2000). Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. Proc. Natl. Acad. Sci. USA. 97, 761-766.
21. VINCENT, A., LEITE, M.I., FARRUGIA, M.E., JACOB, S., VIEGAS, S., SHIRAISHI, H., BENVENISTE, O., MORGAN, B.P., HILTON-JONES, D., NEWSOM-DAVIS, J., BEESON, D., and WILLCOX, N. (2008). Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann. N. Y. Acad. Sci. 1132, 84-92. (Pubitemid 351841363)
22. VINCENT, A., PALACE, J., and HILTON-JONES, D. (2001). Myasthenia gravis. Lancet. 357, 2122-2128.
23. VINCENT, A., WHITING, P.J., SCHLUEP, M., HEIDENREICH, F., LANG, B., ROBERTS, A., WILLCOX, N., and NEWSOM-DAVIS, J. (1987). Antibody heterogeneity and specif city in myasthenia gravis. Ann. N. Y. Acad. Sci. 505, 106-120. (Pubitemid 18146146)
24. ZUKER, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415.